Natixis Advisors, L.P. Neurocrine Biosciences Inc Transaction History

Natixis Advisors, L.P.

$54.1 Billion
Q1 2025

A detailed history of Natixis Advisors, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 33,312 shares of NBIX stock, worth $4.15 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

33,312

Previous 33,604 0.87%

Holding current value

$4.15 Million

Previous $4.59 Million 19.69%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$107.22 - $153.29 $31,308 - $44,760	-292 Reduced 0.87%	33,312 $3.68 Million
Q4 2024 Feb 10, 2025	BUY	$111.62 - $139.44 $477,398 - $596,384	4,277 Added 14.58%	33,604 $4.59 Million
Q3 2024 Nov 06, 2024	SELL	$114.58 - $153.15 $679,803 - $908,638	-5,933 Reduced 16.83%	29,327 $3.38 Million
Q2 2024 Aug 01, 2024	BUY	$130.86 - $143.19 $462,066 - $505,603	3,531 Added 11.13%	35,260 $4.85 Million
Q1 2024 Apr 25, 2024	BUY	$130.4 - $143.74 $247,499 - $272,818	1,898 Added 6.36%	31,729 $4.38 Million
Q4 2023 Feb 06, 2024	SELL	$106.07 - $132.76 $54,307 - $67,973	-512 Reduced 1.69%	29,831 $3.93 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $523,973 - $652,598	5,573 Added 22.5%	30,343 $3.41 Million
Q2 2023 Aug 15, 2023	SELL	$89.53 - $104.87 $2.64 Million - $3.09 Million	-29,481 Reduced 54.34%	24,770 $2.34 Million
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $653,217 - $853,881	-6,941 Reduced 11.34%	54,251 $5.49 Million
Q4 2022 Jan 27, 2023	SELL	$106.72 - $127.06 $989,294 - $1.18 Million	-9,270 Reduced 13.16%	61,192 $7.31 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $337,474 - $395,339	3,667 Added 5.49%	70,462 $7.48 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $488,542 - $645,051	6,446 Added 10.68%	66,795 $6.51 Million
Q1 2022 May 12, 2022	BUY	$72.45 - $94.81 $2.37 Million - $3.1 Million	32,746 Added 118.63%	60,349 $5.66 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $1.07 Million - $1.43 Million	-13,419 Reduced 32.71%	27,603 $2.35 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $507,600 - $583,286	5,890 Added 16.77%	41,022 $3.93 Million
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $97,836 - $111,883	1,094 Added 3.21%	35,132 $3.42 Million
Q1 2021 May 05, 2021	BUY	$87.57 - $119.4 $319,980 - $436,287	3,654 Added 12.03%	34,038 $3.31 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $315,657 - $393,454	-3,632 Reduced 10.68%	30,384 $2.91 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $1.83 Million - $2.57 Million	19,003 Added 126.58%	34,016 $3.27 Million
Q2 2020 Aug 11, 2020	BUY	$85.09 - $130.36 $37,950 - $58,140	446 Added 3.06%	15,013 $1.83 Million
Q1 2020 Apr 27, 2020	BUY	$75.11 - $113.76 $211,359 - $320,120	2,814 Added 23.94%	14,567 $1.26 Million
Q4 2019 Feb 10, 2020	BUY	$86.8 - $118.57 $98,518 - $134,576	1,135 Added 10.69%	11,753 $1.26 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $890,000 - $1.08 Million	10,618 New	10,618 $957,000

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Neurocrine Biosciences Inc Transaction History